Cargando…

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder

BACKGROUND: We evaluated the effects of once-daily extended-release quetiapine fumarate (quetiapine XR) on patient-reported outcomes in generalized anxiety disorder (GAD). METHODS: This is a report of a pooled analysis from three acute 8-week, randomized, placebocontrolled, fixed-dose (50, 150, 300...

Descripción completa

Detalles Bibliográficos
Autores principales:	Endicott, Jean, Svedsäter, Henrik, Locklear, Julie C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404593/ https://www.ncbi.nlm.nih.gov/pubmed/22848184 http://dx.doi.org/10.2147/NDT.S32320

Ejemplares similares

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili, Nizar
Publicado: (2012)

The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens, Joseph
Publicado: (2011)

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
por: Wang, Gang, et al.
Publicado: (2014)

The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population
por: Pan, Pei-Yin, et al.
Publicado: (2015)

Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study
por: Chen, Yi-Chih, et al.
Publicado: (2012)

Role of extended release quetiapine in the management of bipolar disorders
por: Al Jurdi, Rayan K, et al.
Publicado: (2010)

The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2019)

Comparison of D(2) dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects
por: Nord, Magdalena, et al.
Publicado: (2011)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
por: Atsuta, Ryo, et al.
Publicado: (2018)

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union
por: Brody, Robert S., et al.
Publicado: (2018)

Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication
por: Chapman, Sarah, et al.
Publicado: (2017)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Branch retinal vein occlusion associated with quetiapine fumarate
por: Yong, Ku Chui, et al.
Publicado: (2011)

Quetiapine N-oxide–fumaric acid (2/1)
por: Shen, Jin, et al.
Publicado: (2012)

Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia
por: Akhlaq, Muhammad, et al.
Publicado: (2018)

Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane
por: Bhupathyraaj, Mullaicharam, et al.
Publicado: (2022)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy
por: Svedsater, Henrik, et al.
Publicado: (2016)

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Baune, Bernhard T
Publicado: (2008)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib
por: Lamba, M, et al.
Publicado: (2017)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder
por: McIntyre, Roger S., et al.
Publicado: (2015)

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy
por: Stynes, Gillian, et al.
Publicado: (2015)

Economic and humanistic burden of illness in generalized anxiety disorder: an analysis of patient survey data in Europe
por: Toghanian, Samira, et al.
Publicado: (2014)

Correction: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Formulation Design and Optimization of Orodispersible Tablets of Quetiapine Fumarate by Sublimation Method
por: Kalyankar, P., et al.
Publicado: (2015)

Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended‐Release Once‐Daily Tacrolimus Tablets
por: Philosophe, Benjamin, et al.
Publicado: (2018)

Rhabdomyolysis following Acute Extended-Release Quetiapine Poisoning: A Case Report
por: Liolios, Antonios, et al.
Publicado: (2012)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
por: Yone, Eric W Pefura, et al.
Publicado: (2012)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

Quality by Design Approach for Development and Characterisation of  Solid Lipid Nanoparticles of Quetiapine Fumarate
por: Agarwal, Shweta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2okeupvetahnkpn6vjeefvgtce